免疫性血小板减少症患者接种SARS-CoV-2疫苗的真实世界单中心经验
该单中心回顾性分析纳入294例活跃随访的免疫性血小板减少症(ITP)患者,接种SARS-CoV-2疫苗后ITP复发率为6.6%,新诊断ITP发生率为1.4%。接种后血小板计数较基线显著偏离(P≤.0001),17例中16例(94%)需治疗干预,随访结束时4例(24%)仍对治疗无反应且血小板计数<30×10^9/L。
要点
- 294例ITP患者接种SARS-CoV-2疫苗后复发率6.6%,新诊断ITP发生率1.4%。
- 接种后血小板计数较基线显著偏离(P≤.0001),17例中15例(88%)出现症状。
- 17例中16例(94%)需治疗干预,随访结束时4例(24%)仍无反应且血小板<30×10^9/L。
核心结论
- ITP患者接种SARS-CoV-2疫苗仍具有重要临床获益,但针对复发患者的推荐仍缺乏。
- 本报告描述了SARS-CoV-2疫苗广泛接种时代的真实世界患者结局。
研究设计与样本
- 单中心真实世界队列,回顾性审查294例活跃随访ITP患者的疫苗接种状态。
- 识别17例接种SARS-CoV-2疫苗后ITP复发患者,复发率6.6%,新诊断ITP发生率1.4%。
主要发现
- 接种后患者血小板计数较基线出现显著偏离(P≤.0001)。
- 17例中14例既往诊断为ITP,诊断后中位随访4年(范围0-45年)。
- 从接种到就诊间隔2-42天(中位14天),随访期34周。
- 17例中15例(88%)就诊时有症状,全部17例在随访期内出现症状。
- 随访期内9例(53%)接种第二剂疫苗,其中7例(78%)需治疗支持以完成第二剂接种。
关键数值与推荐
- 治疗决策为多因素综合判断,目标为减轻出血症状并使血小板计数>30×10^9/L。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune thrombocytopenic purpura (ITP) relapse following vaccination remains poorly reported in the adult population. OBJECTIVES: This report details real world data from the largest single-center cohort of ITP relapse following severe acute respiratory syndrome (SARS-CoV-2) vaccination. METHODS: The vaccination status of 294 patients under active follow-up was reviewed. A total of 17 patients were identified resulting in an incidence of ITP relapse following SARS-CoV-2 vaccination in this cohort of 6.6% and an incidence of newly diagnosed ITP following SARS-CoV-2 vaccination of 1.4%. RESULTS: Patients were noted to develop marked deviation of platelet count from baseline following vaccination (P =< .0001). Fourteen patients had a prior diagnosis of ITP and median follow-up following diagnosis was 4 years (range 0-45 years). Days from vaccination to presentation ranged from 2-42 (median 14) and the follow-up period was 34 weeks. Fifteen patients (88%) presented with symptoms and all 17 patients developed symptoms during the follow-up period. Nine patients (53%) received a second dose of vaccine during the follow-up period with seven patients (78%) requiring therapeutic support to facilitate second vaccination. Decision to treat patients was multi-factorial and aimed at decreasing bleeding symptoms and obtaining a platelet count >30 × 109 /L. Sixteen patients (94%) required therapeutic intervention and at the end of the follow-up period, four patients (24%) remained unresponsive to treatment with a platelet count <30 × 109 /L. CONCLUSION: Vaccination of ITP patients continues to have important clinical benefit; however, recommendations for patients who relapse remain lacking. This report outlines the real-world patient outcomes in the era of widespread SARS-CoV-2 vaccination.
引用
- Woolley P, Tailor A, Shah R, et al. Real-world, single-center experience of SARS-CoV-2 vaccination in immune thrombocytopenia. J Thromb Haemost. 2022. PMID: 35313390. doi:10.1111/jth.15704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。